Published in Atherosclerosis on June 10, 2014
Lifestyle modification interventions differing in intensity and dietary stringency improve insulin resistance through changes in lipoprotein profiles. Obes Sci Pract (2016) 0.75
Interleukin-6 "Trans-Signaling" and Ischemic Vascular Disease: The Important Role of Soluble gp130. Mediators Inflamm (2017) 0.75
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 33.22
Inflammation in atherosclerosis. Nature (2002) 28.92
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA (2002) 25.68
Inflammation and atherosclerosis. Circulation (2002) 20.77
Abdominal obesity and metabolic syndrome. Nature (2006) 14.20
Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc (2000) 10.19
Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care (2000) 9.10
Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation (2004) 7.77
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med (1999) 6.92
The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol (2010) 5.54
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet (2008) 4.70
C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med (2009) 3.50
C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation (2004) 3.25
C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation (2005) 2.48
The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J (2007) 2.44
Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care (2007) 2.03
Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol (2006) 1.66
Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int (2000) 1.62
Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med (2008) 1.36
Ectopic lipid storage and insulin resistance: a harmful relationship. J Intern Med (2013) 1.22
Interleukin-6, C-reactive protein, and tumor necrosis factor-alpha as predictors of mortality in frail, community-living elderly individuals. J Am Geriatr Soc (2011) 1.20
Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study. PLoS One (2012) 1.14
High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study. Neurology (2009) 1.05
Mortality in people diagnosed with type 2 diabetes at an older age: a systematic review. Age Ageing (2006) 1.04
Insulin resistance predicts mortality in nondiabetic individuals in the U.S. Diabetes Care (2010) 1.04
C-reactive protein and metabolic syndrome in elderly women: a 12-year follow-up study. Diabetes Care (2006) 0.99
C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study. Eur Heart J (2005) 0.97
Metabolic syndrome and all-cause and cardiovascular mortality in an Italian elderly population: the Progetto Veneto Anziani (Pro.V.A.) Study. Diabetes Care (2008) 0.97
Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance. Atherosclerosis (2010) 0.96
Metabolic syndrome and risk of mortality in middle-aged versus elderly individuals: the Nord-Trøndelag Health Study (HUNT). Diabetologia (2009) 0.95
Metabolic syndrome, its components, and mortality in the elderly. J Clin Endocrinol Metab (2010) 0.88
The impact of the metabolic syndrome--but not of hypertension--on all-cause mortality disappears in the elderly. J Hypertens (2011) 0.88
Insulin resistance, cystatin C, and mortality among older adults. Diabetes Care (2012) 0.88
Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol (2012) 0.84
Hip fractures: comprehensive geriatric care and recovery. Lancet (2015) 0.78
Effect of structured physical activity on prevention of serious fall injuries in adults aged 70-89: randomized clinical trial (LIFE Study). BMJ (2016) 0.77
Ischemia-related changes in circulating stem and progenitor cells and associated clinical characteristics in peripheral artery disease. Vasc Med (2015) 0.76
Community walking speed, sedentary or lying down time, and mortality in peripheral artery disease. Vasc Med (2016) 0.75
Combining LDL-C and HDL-C to predict survival in late life: The InChianti study. PLoS One (2017) 0.75